Cargando…
Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
BACKGROUND: Use of hydroxychloroquine (HCQ) is common in patients with lupus erythematosus. Long-term use (ie, ≥5 years) and high-dose HCQ (ie, >5 mg/kg/day) are both risk factors for developing HCQ retinopathy. Advances in our understanding of HCQ retinopathy have led to changes in the recommend...
Autores principales: | Osmani, Zgjim, Schrama, Thijs J, Zacouris-Verweij, Wendy, Andersen, Jeanette, Frankel, Susan, Bultink, Irene E M, Cornet, Alain, van Vollenhoven, Ronald F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021889/ https://www.ncbi.nlm.nih.gov/pubmed/33795484 http://dx.doi.org/10.1136/lupus-2021-000478 |
Ejemplares similares
-
Coping with systemic lupus erythematosus in patients’ words
por: Cornet, Alain, et al.
Publicado: (2022) -
Living with systemic lupus erythematosus in 2020: a European patient survey
por: Cornet, Alain, et al.
Publicado: (2021) -
Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety
por: Cornet, Alain, et al.
Publicado: (2021) -
Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus
por: Vázquez-Otero, Ileana, et al.
Publicado: (2020) -
Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)